In this model, knock-down of Socs2 also decelerated leukemia onset in mice, promoted LC differentiation, and reduced the abundance, quiescence, and activity of LSCs (Fig. 5D–H), the LC subpopulation that acts as driver of the disease and is responsible for therapy resistance and relapse1. Here, SOCS2 is linked to leukemia.